骨肉瘤组织中微小RNA-650的表达变化及其意义

doi:10.3969/j.issn.1006-6233.2022.07.012

摘要
图/表
参考文献
相关文章 (4)

全文: PDF (1275 KB) HTML (1 KB)
输出: BibTeX | EndNote (RIS)

摘要 目的: 探讨骨肉瘤(OS)组织中微小RNA(miR)-650的表达特点,分析miR-650与临床病理参数和预后的关系。方法: 取80例经手术切除的骨肉瘤组织标本以及瘤旁正常组织标本(距离瘤组织>5cm),采用实时PCR法检测组织中miR-650表达,根据骨肉瘤组织miR-650表达均数将患者分为miR-650高表达组(miR-650≥5.03,42例)、miR-650低表达组(miR-650<5.03,38例)。收集患者临床病理参数相关信息,比较不同临床病理参数患者miR-650表达差异。术后定期随访3年,采用Kaplan-Meier、COX风险比例回归分析miR-650与骨肉瘤患者预后的关系。结果: 骨肉瘤组织miR-650相对表达量高于瘤旁组织(P<0.001),miR-650与OS患者Enneking分期、淋巴结转移、远处转移有关(P<0.001)。Kaplan-Meier生存曲线分析结果显示miR-650高表达组OS患者3年生存率低于miR-650低表达组(P<0.01)。淋巴结转移[OR=1.545(95%:1.474~1.635)]、远处转移[OR=1.702(95%:1.664~1.815)]、miR-650≥5.03[OR=1.645(95%:1.564~1.748)]是OS患者死亡的危险因素(P<0.01)。结论: 骨肉瘤组织织miR-650表达升高,miR-650表达与患者Enneking分期、淋巴结转移、远处转移及预后密切相关,可能作为OS预后评估的标记物及治疗靶点。

	服务

	把本文推荐给朋友
	加入我的书架
	加入引用管理器
	E-mail Alert
	RSS
	作者相关文章
	杜壮文
	欧阳帆
	曾繁宽

关键词 ：骨肉瘤, miR-650, 临床病理参数

Abstract：Objective: To investigate the expression characteristics of miR-650 in osteosarcoma (OS) tissue,and to analyze the relationship between miR-650 and clinicopathological parameters and prognosis. Methods: Eighty osteosarcoma tissue specimens and paraneoplastic tissue specimens (>5 cm from the tumour) were collected after surgical resection,and real-time PCR was used to detect the expression of miR-650 in tissues,according to the mean expression of miR-650 in OS group,the patients were divided into high expression group of miR-650 (miR-650≥5.03,42 cases) and low expression group of miR-650 (miR-650 < 5.03,38 cases).Information regarding the clinicopathological parameters of patients was collected to compare the differences in miR-650 expression in patients with different clinicopathological parameters.The relationship between miR-650 and prognosis of patients with osteosarcoma was analysed using Kaplan-Meier,COX risk proportion regression at regular follow-up for 3 years after surgery. Results: The relative expression level of miR-650 in osteosarcoma tissue was higher than that in paratumoral tissue (P<0.001),and miR-650 was associated with Enneking stage,lymph node metastasis and distant metastasis in OS patients (P<0.001).Kaplan-Meier survival curve analysis showed that the 3 years survival rate of OS patients in the group with high miR-650 expression was lower than that in the group with low miR-650 expression (P<0.01).Multivariate Cox risk ratio regression analysis showed that lymphatic metastasis[OR=1.545(95%:1.474~1.635)],distant metastasis[OR=1.702(95%:1.664~1.815)],miR-650≥5.03[OR=1.645(95%:1.564~1.748)] were risk factors for death in OS patients (P<0.01). Conclusion: The expression of miR-650 in OS tissues is elevated,which is closely related to the clinicopathological characteristics and prognosis of patients,and may be used as a marker and therapeutic target for the prognosis evaluation of OS.

Key words： Osteosarcoma MiR-650 Clinicopathological parameters

基金资助:海南省卫生健康行业科研项目,(编号:20A200087)

引用本文:

杜壮文, 欧阳帆, 曾繁宽. 骨肉瘤组织中微小RNA-650的表达变化及其意义[J]. 河北医学, 2022, 28(7): 1107-1112.
DU Zhuangwen, OUYANG Fan, ZENG Fankuan. Changes in the Expression of MicroRNA-650 in Osteosarcoma Tissues and Its Significance. HeBei Med, 2022, 28(7): 1107-1112.

链接本文:

http://www.hbyxzzs.cn/CN/10.3969/j.issn.1006-6233.2022.07.012 或 http://www.hbyxzzs.cn/CN/Y2022/V28/I7/1107

[1] Harrison D J,Geller D S,Gill J D,et al.Current and future therapeutic approaches for osteosarcoma[J].Expert Rev Anticancer Ther,2018,18(1):39-50.
[2] Xu L,Yu QW,Fang SQ,et al.MiR-650 inhibits the progression of glioma by targeting FAM83F[J].Eur Rev Med Pharmacol Sci,2018,22(23):8391-8398.
[3] Tang X,Ding Y,Wang X,et al.miR-650 promotes non-small cell lung cancer cell proliferation and invasion by targeting ING4 through Wnt-1/β-catenin pathway[J].Oncol Lett,2019,18(5):4621-4628.
[4] Wang F,Zhao QH,Liu JZ,et al.MiRNA-188-5p alleviates the progression of osteosarcoma via target degrading CCNT2[J].Eur Rev Med Pharmacol Sci,2020,24(1):29-35.
[5] Liu X,Cui M.MiRNA-98-5p inhibits the progression of osteosarcoma by regulating cell cycle via targeting CDC25A expression[J].Eur Rev Med Pharmacol Sci,2019,23(22):9793-9802.
[6] Han LL,Yin XR,Zhang SQ.miR-650 promotes the metastasis and epithelial-mesenchymal transition of hepatocellular carcinoma by directly inhibiting LATS2 expression[J].Cell Physiol Biochem,2018,51(3):1179-1192.
[7] Yang YQ,Tian T,Zhu HY,et al.NDRG2 mRNA levels and miR-28-5p and miR-650 activity in chronic lymphocytic leukemia[J].BMC Cancer,2018,18(1):1009.
[8] Zhou C,Cui F,Li J,et al.miR-650 represses high-risk non-metastatic colorectal cancer progression via inhibition of AKT2/GSK3β/E-cadherin pathway[J].Oncotarget,2017,8(30):49534-49547.
[9] Yun JH,Moon S,Lee HS,et al.MicroRNA-650 in a copy number-variable region regulates the production of interleukin 6 in human osteosarcoma cells[J].Oncol Lett,2015,10(4):2603-2609.
[10] 陈贤明,张森,王爱民,等.MiR-650通过靶向ING4促进骨肉瘤细胞增殖的研究[J].重庆医学,2018,47(9):1173-1175.
[11] Ko A,Han S Y,Song J.Regulatory network of ARF in cancer development [J].Molecules and Cells,2018,41(5):381-389.
[12] Bottanelli F,Kilian N,Ernst A M,et al.A novel physiological role for ARF1 in the formation of bidirectional tubules from the golgi[J].Molecular Biology of the Cell,2017,28(12):1676-1687.
[13] Boulay P L,Schlienger S,Lewis-Saravalli S,et al.ARF1 controls proliferation of breast cancer cells by regulating the retinoblastoma protein[J].Oncogene,2011,30(36):3846-3861.